top of page
  • mmahomed2

Series A financing

Updated: Jul 20, 2019

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised over $2.5MM in funding for the continued development of our lead products. As a part of this deal, Walter Moos and Drew Lanza were appointed to our Board of Directors, and we are excited to add their experience as entrepreneurs and investors to the Valitor leadership team. For more information, read our press release.

361 views0 comments

Recent Posts

See All

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

Valitor has recruited and hired Amy Twite, PhD to join our team as Director Chemistry. Amy graduated from UC Berkeley’s College of Chemistry with extensive experience in conjugation chemistry and cell

bottom of page